MedTrace Logo

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

NCT07106827 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-11-24

No results posted yet for this study

Summary

This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.

Conditions

Interventions

DRUG

GV20-0251

Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks

Sponsors & Collaborators

  • GV20 Therapeutics

    collaborator INDUSTRY

  • West China Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-04
Primary Completion
2027-06-11
Completion
2028-06-11

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07106827 on ClinicalTrials.gov